{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T20:03:28Z","timestamp":1787342608030,"version":"build-2736575974"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100017702","name":"Innovation and Entrepreneurship Talent Project of Lanzhou","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100017702","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018528","name":"Liuzhou Science and Technology Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018528","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2018-3-50"],"award-info":[{"award-number":["2018-3-50"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007764","name":"Lanzhou Science and Technology Bureau","doi-asserted-by":"publisher","award":["2018-RC-74"],"award-info":[{"award-number":["2018-RC-74"]}],"id":[{"id":"10.13039\/501100007764","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.msard.2020.102421","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T12:14:43Z","timestamp":1595506483000},"page":"102421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"45","author":[{"given":"QinFang","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengJiao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ManXia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.msard.2020.102421_bib0001","doi-asserted-by":"crossref","first-page":"1302\u20101306","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2020.102421_bib0002","doi-asserted-by":"crossref","first-page":"394\u2010397","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102421_bib0003","doi-asserted-by":"crossref","first-page":"480\u2010489","DOI":"10.1111\/cei.12733","article-title":"Prediction of disease severity in neuromyelitis optica by the levels of interleukin (IL)-6 produced during remission phase","volume":"183","author":"Barros","year":"2016","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2020.102421_bib0004","doi-asserted-by":"crossref","first-page":"3701\u20103706","DOI":"10.1073\/pnas.1017385108","article-title":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica","volume":"108","author":"Chihara","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.msard.2020.102421_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/cen3.12103","article-title":"Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies","volume":"5","author":"Iorio","year":"2014","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.msard.2020.102421_bib0006","doi-asserted-by":"crossref","first-page":"301\u2010;306","DOI":"10.1016\/j.intimp.2016.03.016","article-title":"Clinical effects of tocilizumab on cytokines and immunological factors in patients with rheumatoid arthritis","volume":"35","author":"Kasama","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2020.102421_bib0007","article-title":"Effectiveness of subcutaneous tocilizumab in neuromyelitis optica spectrum disorders [published online ahead of print, 2019 Dec 30]","volume":"39","author":"Lotan","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"Pt 7","key":"10.1016\/j.msard.2020.102421_bib0008","first-page":"1450\u20101461","article-title":"A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.msard.2020.102421_bib0009","first-page":"w13518","volume":"142","author":"Nordmann","year":"2012"},{"issue":"6","key":"10.1016\/j.msard.2020.102421_bib0010","doi-asserted-by":"crossref","first-page":"554\u2010562","DOI":"10.1016\/S1474-4422(13)70076-0","article-title":"Eculizumab in AQP4-IgG-positive relapsing neuromyelitis optica spectrum disorders: an open-label pilot study","volume":"12","author":"Pittock","year":"2013","journal-title":"Lancet Neurol."},{"issue":"7","key":"10.1016\/j.msard.2020.102421_bib0011","doi-asserted-by":"crossref","first-page":"756\u2010763","DOI":"10.1001\/jamaneurol.2015.0533","article-title":"Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder","volume":"72","author":"Ringelstein","year":"2015","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2020.102421_bib0012","doi-asserted-by":"crossref","first-page":"314\u2010322","DOI":"10.1002\/ana.22657","article-title":"Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica","volume":"71","author":"Tradtrantip","year":"2012","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2020.102421_bib0013","first-page":"67\u201073","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications [published correction appears in Brain Pathol. 2014 Jul;24(4):428. Masahiro, Mori [corrected to Mori, Masahiro]]","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2020.102421_bib0014","doi-asserted-by":"crossref","first-page":"181\u2010;183","DOI":"10.1016\/j.cca.2013.03.020","article-title":"Cerebrospinal fluid interleukin-6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica attacks","volume":"421","author":"Uzawa","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.msard.2020.102421_bib0015","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.msard.2020.102421_bib0016","first-page":"665\u2010;688","article-title":"Neuromyelitis optica: new findings on pathogenesis","volume":"79","author":"Wingerchuk","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"issue":"5","key":"10.1016\/j.msard.2020.102421_bib0017","doi-asserted-by":"crossref","first-page":"1107\u20101114","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2020.102421_bib0018","doi-asserted-by":"crossref","first-page":"2329\u20102335","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2020.102421_bib0019","doi-asserted-by":"crossref","first-page":"391\u2010401","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030496X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482030496X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:27:47Z","timestamp":1778840867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482030496X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":19,"alternative-id":["S221103482030496X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102421","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis to determine the efficacy and safety of tocilizumab in neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102421"}}